Navigation Links
Targeted therapy decreases progression rate in thyroid cancer
Date:9/17/2010

ROCHESTER, Minn. -- The drug pazopanib may help revolutionize the care of patients with metastatic, rapidly progressive differentiated thyroid cancers, say researchers at Mayo Clinic who are publishing findings of a phase II clinical trial in The Lancet Oncology.

VIDEO ALERT: Additional audio and video resources, including excerpts from an interview with Dr. Keith Bible describing the research, are available on the Mayo Clinic News Blog. Password: bible.

The researchers studied 37 patients with the most aggressive form of this cancer -- developing in less than 5 percent of patients with differentiated thyroid cancer -- and found that about half (18) patients had a long-lasting response to pazopanib. Of that group, 12 are still alive without disease progression. The median progression-free survival time was 11.7 months, with an overall survival rate of 81 percent at one year.

The researchers say that, to their knowledge, these findings represent by far the highest response rate yet reported in such aggressive cases of differentiated thyroid cancer. They caution however, that this drug is not meant to be used in slow-growing differentiated thyroid cancers and that they cannot assess the survival advantage pazopanib offers to the patients studied.

Determining survival benefit would require a randomized clinical trial testing the agent, which inhibits all three vascular endothelial growth factor (VEGF) receptors, compared to other treatments or a placebo.

"In this group of patients, we would have expected the cancer to have progressed in everyone within six months, but instead the median time to progression was almost a year in response to pazopanib therapy," says Keith Bible, M.D., Ph.D., a medical oncologist and researcher who led the multicenter clinical trial, funded by the National Cancer Institute. Most of the patients treated were enrolled at Mayo Clinic campuses in Minnesota and Florida.

But as encouraging as this response is, it does not come without the potential for significant side effects, Dr. Bible says. The drug dose used in 16 patients had to be lowered because side effects were judged by oncologists to become potentially threatening or debilitating, and two patients experienced significant bleeding. Further, although two patients died in association with pre-existing disease while enrolled in the study, the agent could have contributed in some way, he says.

"Further studies of pazopanib in advanced thyroid cancer remain ongoing at Mayo Clinic and associated cancer centers to continue to learn more about how best to use the drug in these cancers," Dr. Bible says. "Such clinical trials also may provide patients access to this drug, which otherwise may be unobtainable due to cost, given that it is not yet approved for use in thyroid cancers."

Plans are underway for a larger phase III clinical trial with aggressive differentiated thyroid cancer patients that will be centered in Europe, with some sites to be opened in the U.S.

The authors declare no conflicts of interest. The manufacturer of pazopanib (GlaxoSmithKline) did not provide funding or other material support to the researchers and did not have access to the data.


'/>"/>

Contact: Nicole Engler
engler.nicole@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Targeted agent shows promise for chronic lymphoid leukemia
2. Targeted strategies needed to find, prevent and treat breast cancer among Mexican-origin women
3. In Early Trial, Targeted Therapy Fights Advanced Melanoma
4. New targeted therapy for advanced melanoma associated with 80 percent response rate
5. Targeted drug leads to regression of metastatic melanoma with mutated BRAF gene
6. NYU Langone offers vascular-targeted photodynamic therapy for localized prostate cancer
7. Radiation device allows for targeted breast radiation to control cancer
8. Surveillance colonoscopy should be targeted to high-risk patients
9. Combined BRAF-targeted and immunotherapy shows promise for melanoma treatment
10. Experimental targeted therapy shows early promise against medulloblastomas
11. Targeted Therapy Shows Promise Against Deadly Brain Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/30/2016)... California (PRWEB) , ... May 30, 2016 , ... ... easy to use inside of FCPX," said Christina Austin - CEO of Pixel ... exclusively for use within Final Cut Pro X. Choose from abstract transitions to ...
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is happy to announce ... been available via Amazon.com. This new style of nail clipper has a wider jaw ... is approximately 4mm and the actual handle is 2.5mm thick to accommodate the cutting ...
(Date:5/28/2016)... ... May 28, 2016 , ... "Color Grading media can ... drop a preset onto their media," said Christina Austin - CEO of Pixel Film ... can quickly and easily add stylish color grades to their footage. A LUT is ...
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... May 27, 2016 , ... An influential resource amongst nurses and professionals in ... lights on the variety of topics detailing why we appreciate nurses in so many ... career has gone from being in a major recession to one of the hottest ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... biopharmaceutical company focused on late-stage drug development, today ... Pharma of pivotal batches required for registration ... Administration (FDA). This follows Kitov,s announcement ... trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... May 26, 2016 TARE ... Both Cost Savings and Overall Decreased Use ... BTG), an international specialist healthcare company, has today ... 21st Annual Meeting of ISPOR (International Society for ... hepatocellular carcinoma (HCC) using yttrium-90 glass microspheres is ...
(Date:5/25/2016)... GERMANTOWN, Maryland , May 25, 2016 /PRNewswire/ ... dringenden Bedarf zur Steuerung ... N.V. (NASDAQ: QGEN ; Frankfurt Prime ... Entwicklungsvereinbarung mit Therawis Diagnostics GmbH zur Entwicklung und ... sein. Ein erstes Projekt wird die Entwicklung und ...
Breaking Medicine Technology: